might interest some....Bristol Myers beats estimates with new drug sales surge
Bristol Myers Squibb ($BMY) outperformed in Q4 with adjusted earnings per share of $1.70 (compared to the expected $1.53) and revenue of $11.48B (surpassing the expected $11.19B). The sales boost was driven by higher sales of new drugs, including Reblozyl and Opdualag, contributing $1.07B, up 66% from the previous year.
fwiw...Opdualag had sales of $190M for 4th qtr of 2023, contrast this with sales of $45M for 3rd qtr 2022..
- Forums
- ASX - By Stock
- IMM
- Media
Media, page-617
-
- There are more pages in this discussion • 127 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
28.8¢ |
Change
-0.013(4.17%) |
Mkt cap ! $417.6M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 28.8¢ | $104.5K | 358.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 320304 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 189978 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
23 | 320832 | 0.285 |
24 | 455310 | 0.280 |
8 | 142468 | 0.275 |
13 | 306073 | 0.270 |
7 | 148623 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 189974 | 6 |
0.295 | 162418 | 6 |
0.300 | 580120 | 8 |
0.305 | 186523 | 9 |
0.310 | 540731 | 9 |
Last trade - 10.58am 10/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online